

NEW ORLEANS

School of Medicine

Gabrielle Stone¹, Kaitlin McGrail MD¹, Andrew G Chapple PhD², Elizabeth F Sutton PhD³, **Neill R Chappell MD MSCI⁴**

¹Department of Obstetrics and Gynecology, Louisiana State University Health Sciences Center, Baton Rouge, Louisiana, ²Department of Biostatics, Louisiana State University Health Sciences Center, New Orleans, Louisiana, ³Woman's Hospital, Baton Rouge, Louisiana, ⁴Fertility Answers, Woman's Hospital, Baton Rouge, Louisiana

Introduction

Laparoscopy (LSC) for abdominal surgery has become the standard approach for many surgical interventions to date. While there are numerous benefits to a minimally invasive technique, LSC can also be associated with postoperative referred pain to the shoulder. Laparoscopic (LSC) surgery has added benefits over laparotomy, including shorter hospital stays and potential decrease in postoperative pain leading to decreased opioid use. However, it does require insufflation of the abdomen for visualization, and this is most often achieved with carbon dioxide (CO2) (Figure 1).

While several interventions have been proposed to mitigate this pain, no singular intervention has proven to be superior. Perioperative acetazolamide (ACTZ) administration is a relatively cost effective and safe option, though it is less well recognized, and its efficacy is currently unproven.

ACTZ is a medication that works by inhibiting the carbonic anhydrase enzyme, which is responsible for the conversion of CO2 and water to carbonic acid. The CO2 gas that is used for insufflation is converted to carbonic acid by carbonic anhydrase, leading to intraperitoneal irritation due to acid buildup.

Perioperative administration of ACTZ may decrease the amount of carbonic acid production and thereby decrease diaphragm irritation. This represents a potential costeffective strategy with few side effects or contraindications, making it an ideal option for improving postoperative pain.

This study was designed as a systematic review and meta-analysis to evaluate the efficacy of perioperative ACTZ administration with LSC for reducing postoperative referred pain.

Methods

A systematic literature search was performed and included studies published from inception to March 1, 2020. We included only studies of patients who underwent abdominal LSC, had a pain assessment at approximately 24 hours postoperatively, and included a treatment with ACTZ for pain management group and a no-treatment or minimal-treatment comparison group. Five studies met inclusion criteria, with a combined total of 253 participants, 116 in the ACTZ group and 137 in the control group. A Bayesian hierarchical model was assumed for the study specific treatment effects. Posterior sampling was conducted via Markov Chain Monte Carlo methods, and posterior inference carried out on the hierarchical treatment effect.



Figure 1

Systematic Review and Meta-Analysis of Perioperative Administration of Acetazolamide for Management of **Postoperative Pain After Laparoscopy**

Result	s – Ind	ividual Stu	dy Outo
A summary of the stucholecystectomy [3, 4) who were undergoing procedures, including	idy characteristics is 5]. One study include g inguinal herniorrha g gynecologic, chole	exhibited in Table 1. Two of the streed patients underwent LSC for don phy [4]. The final study included pactors, gastric bypass, hernio	udies involved patients u or nephrectomy [6]. Ano atients receiving LSC for rrhaphy, and lymph node
Study	Study design	Intervention (n)	Outcome
Singh R et al. 2009 ⁶	RCT	 Acetazolamide and bupivacaine (40) Bupivacaine (40) 	Postoperative pain intensity using
Pourladian et al. 2016⁴	Observational	Acetazolamide (22)No acetazolamide (44)	Postoperative pain intensity using
Woehlck HJ et al, 2003 ⁷	RCT	Acetazolamide (18)Saline placebo (20)	Postoperative pain intensity using
Rahimzadeh R et al, 2018 ⁵	RCT	 Acetazolamide (20) Bupivacaine (20) Saline placebo (20) 	Postoperative pain intensity using
Bala I et al, 2015 ³	RCT	 Acetazolamide (20) No Acetazolamide (20) Saline Placebo (20) 	Postoperative pain intensity using
		Table 1	

Results – Effect of Acetazolamide on 24-hour pain score

The average and standard deviation of VAS scores for the ACTZ and control groups used for posterior sampling are shown in Table 2. The largest observed mean difference in 24-hour VAS scores between the control and ACTZ groups was 1.7, which was seen in Pourladian et al. Of interest, the standard deviation of VAS scores in the ACTZ group was smaller than the control group, despite having half the sample size. The weighted average VAS scores across all the studies was 2.45 for the ACTZ group and 3.35 for the control group, respectively. The posterior mean for the hierarchical treatment effect was -0.726 (95% Credible interval = -1.175, -0.264) indicating that ACTZ decreases average pain scores compared to control. The posterior probability that ACTZ reduced pain scores (i.e. P[t<0|Data]) was 0.997. This is nearly definitive evidence that ACTZ can be used therapeutically. The posterior probability that ACTZ decreases mean pain scores by 0.5 or more was 0.846.

Study	N Acetazolamide	Mean (SD) 24hr pain score - Acetazolamide	N Control	V
Singh et al	40	1.15 (1.44)	39	
Pourladian et al	22	2.3 (0.9)	44	
Woehlck et al	14	1.71 (1.98)	14	
Bala et al	20	6 (0.75)	20	
Rahimzadeh et al	20	2.22 (0.63)	20	



Referred pain. The sites for referred pain from various organs are shown.



- validity of our findings allows consideration for this intervention to be applicable across the minimally invasive spectrum.
- Our study design does not allow for any conclusions to be drawn regarding adverse side effects of acetazolamide, though the studies reporting on adverse events were overall reassuring.
- A well-defined, blinded, prospective randomized trial with a set dose of acetazolamide compared with placebo would be most appropriate to further knowledge in this area.



Missing data	Measurement of outcomes	Selection of the reported result	Overall rating of bias
Low	Mod- erate	Low	Low